All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2022-06-06T13:27:21.000Z

EHA2022 abstracts: What's hot in multiple myeloma?

By Marta Llobet-Canela, Becky Gribbell, Ella Dixon
Featured
Elena Zamagni
Heinz Ludwig
Hermann Einsele
María-Victoria Mateos
Miles Prince
Paul Richardson
Sagar Lonial
Sonja Zweegman
Jun 6, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in multiple myeloma.

Bookmark this article

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.

Newly diagnosed multiple myeloma

LB2366

Phase 3 DETERMINATION trial in newly diagnosed multiple myeloma: lenalidomide, bortezomib and dexamethasone (RVD) ± autologous stem cell transplantation and lenalidomide maintenance to progression

S175

ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma

S176

Daratumumab, carfilzomib, lenalidomide, and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04

S178

Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology

S179

Randomized comparison between KRd and KTd induction, followed by K maintenance or observation in transplant non-eligible patients with NDMM (AGMT-MM02 trial)

Relapsed/refractory multiple myeloma

S103

Efficacy and safety of ARI0002H, an academic BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in patients with relapsed/refractory multiple myeloma

S184

Evaluating teclistamab in patients with relapsed/ refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents

S185

CARTITUDE-2 Cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy

S188

Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: Updated phase 1b results

S263

Phase I open-label single arm study of GPRC5D CAR-T cells (ORICAR-017) In patients with relapsed/refractory multiple myeloma (POLARIS)

P1463

Phase I dose escalation of LAVA-051, a novel bispecific gamma-delta T-cell engager (GAMMABODY™), in relapsed/refractory hematological malignancies

Other

S244

Effect of anti-spike neutralizing monoclonal antibodies on COVID-19 progression and time to viral clearance in patients with hematological malignancies and SARS-COV-2 infection: The GIMEMA experience

P914

Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: A phase 2 study by the European Myeloma Network

EHA2022 abstracts

To download this document, click below.

Download here

More about...
AL amyloidosisBCMA CAR-TBelantamab mafodotinCAR therapyCarfilzomibCARTITUDE-2Ciltacabtagene autoleucelCOVID-19DaratumumabEHAEHA 2022High-riskLenalidomideNewly diagnosed multiple myelomaRelapsed/refractory multiple myelomaT-cell engagersTeclistamab

Your opinion matters

Which dosing schedule for belantamab mafodotin do you think is optimal for providing an efficacy benefit while managing toxicities?
2 votes - 42 days left ...

Related articles

Add bookmark

EHA 2024 abstracts: What’s hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA 2024 Congress, the Multiple Myeloma Hub Steering Committee has provided recommendations for the top abstracts to look out for in...

Jun 10, 2024
Add bookmark

EHA 2024 abstracts: What’s hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA 2024 Congress, the Multiple Myeloma Hub Steering Committee has provided...

Jun 10, 2024
Add bookmark

Selecting the best regimen at first relapse

During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to select the best regimen at first relapse. The recorded discussion was chaired by...

Jan 25, 2023
Add bookmark

Selecting the best regimen at first relapse

During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to select the best regimen at first...

Jan 25, 2023

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox